Cargando…

Evaluation of IGF1/IGFBP3 Molar Ratio as an Effective Tool for Assessing the Safety of Growth Hormone Therapy in Small-for-gestational-age, Growth Hormone-Deficient and Prader-Willi Children

OBJECTIVE: IGF1 concentration is the most widely used parameter for the monitoring and therapeutic adaptation of recombinant human growth hormone (rGH) treatment. However, more than half the variation of the therapeutic response is accounted for by variability in the serum concentrations of IGF1 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaddas, Meriem, Périn, Laurence, Le Bouc, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745465/ https://www.ncbi.nlm.nih.gov/pubmed/30759961 http://dx.doi.org/10.4274/jcrpe.galenos.2019.2018.0277

Ejemplares similares

Prader-Willi Syndrome and Growth Hormone Deficiency
por: Aycan, Zehra, et al.
Publicado: (2014)

SNORD116 and growth hormone therapy impact IGFBP7 in Prader–Willi syndrome
por: Eddiry, Sanaa, et al.
Publicado: (2021)

Growth Hormone Therapy in Adults with Prader-Willi Syndrome
por: Vogt, Karen S., et al.
Publicado: (2015)

Growth hormone therapy for Prader–willi syndrome: challenges and solutions
por: Grugni, Graziano, et al.
Publicado: (2016)

Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome
por: Dağdeviren Çakır, Aydilek, et al.
Publicado: (2021)

Effect of growth hormone on bone fragility in patients with Prader-Willi syndrome scoliosis
por: Nakamura, Yutaka, et al.
Publicado: (2015)

Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis
por: Rosenberg, Anna G W, et al.
Publicado: (2021)

Growth hormone treatment for adults with Prader-Willi syndrome: another point of view
por: Hirsch, Harry J., et al.
Publicado: (2021)

Glucagon stimulation test to assess growth hormone status in Prader–Willi syndrome
por: Casamitjana, L., et al.
Publicado: (2020)

Response to low dose growth hormone treatment in infants and toddlers with Prader-Willi Syndrome
por: Scheermeyer, Elly, et al.
Publicado: (2015)

EFFECT OF GROWTH HORMONE THERAPY IN CHILDREN WITH PRADER-WILLI SYNDROME – OUR FIRST EXPERIENCES
por: Stipančić, Gordana, et al.
Publicado: (2018)

Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis
por: Passone, Caroline de Gouveia Buff, et al.
Publicado: (2020)

Time for a general approval of growth hormone treatment in adults with Prader–Willi syndrome
por: Höybye, Charlotte, et al.
Publicado: (2021)

Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults With Prader-Willi Syndrome
por: Shukur, Hasanain Hamid, et al.
Publicado: (2021)

Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome
por: Deal, Cheri L., et al.
Publicado: (2013)

Prevalence of growth hormone (GH) deficiency in previously GH‐treated young adults with Prader‐Willi syndrome
por: Donze, Stephany H., et al.
Publicado: (2019)

Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader-Willi-syndrome
por: Magill, Lucy, et al.
Publicado: (2020)

Genetic Subtype-Phenotype Analysis of Growth Hormone Treatment on Psychiatric Behavior in Prader-Willi Syndrome
por: Montes, Andrea S., et al.
Publicado: (2020)

Molecular Classes and Growth Hormone Treatment Effects on Behavior and Emotion in Patients with Prader–Willi Syndrome
por: Mahmoud, Ranim, et al.
Publicado: (2022)

P006 The Impact of Growth Hormone Treatment on Cardiovascular Control in Children with Prader-Willi syndrome
por: Patoglu, O, et al.
Publicado: (2023)

Growth Hormone (GH) Treatment Decreases Plasma Kisspeptin Levels in GH-Deficient Adults with Prader–Willi Syndrome
por: Giménez-Palop, Olga, et al.
Publicado: (2021)

Effects of Childhood Multidisciplinary Care and Growth Hormone Treatment on Health Problems in Adults with Prader-Willi Syndrome
por: Pellikaan, Karlijn, et al.
Publicado: (2021)

Sleep‐disordered breathing in Australian children with Prader‐Willi syndrome following initiation of growth hormone therapy
por: Caudri, Daan, et al.
Publicado: (2021)

Effects of early recombinant human growth hormone treatment in young Chinese children with Prader–Willi syndrome
por: Gao, Ying, et al.
Publicado: (2023)

A Personalized Approach to Determining the Caloric Needs of Children with Prader–Willi Syndrome Treated with Growth Hormone
por: Couto-Rosende, Yolanda, et al.
Publicado: (2023)

A boy with Prader-Willi syndrome: unmasking precocious puberty during growth hormone replacement therapy
por: Ludwig, Natasha G., et al.
Publicado: (2016)

Respiratory Depression in Young Prader Willi Syndrome Patients following Clonidine Provocation for Growth Hormone Secretion Testing
por: Hollman, Gregory A., et al.
Publicado: (2010)

Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
por: Ayet-Roger, Aitana, et al.
Publicado: (2022)

Management of Prader-Labhart-Willi syndrome in children and in adults, with particular emphasis on the treatment with recombinant human growth hormone
por: Drabik, Marta, et al.
Publicado: (2022)

Effects of recombinant human growth hormone in the treatment of dwarfism and relationship between IGF-1, IGFBP-3 and thyroid hormone
por: Ren, Shanxiang, et al.
Publicado: (2016)

Growth Trajectories in Genetic Subtypes of Prader–Willi Syndrome
por: Shepherd, Daisy A., et al.
Publicado: (2020)

Endocrine problems in children with Prader-Willi syndrome: special review on associated genetic aspects and early growth hormone treatment
por: Jin, Dong-Kyu
Publicado: (2012)

Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition
por: Damen, Layla, et al.
Publicado: (2020)

Circulating Levels of Nesfatin-1 and Spexin in Children with Prader-Willi Syndrome during Growth Hormone Treatment and Dietary Intervention
por: Gajewska, Joanna, et al.
Publicado: (2023)

Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency
por: Perez-Colon, Sheila, et al.
Publicado: (2018)

Combined Evaluation of IGF−1 and IGFBP−3 as an Index of Efficacy and Safety in Growth Hormone Treated Patients
por: Şıklar, Zeynep, et al.
Publicado: (2009)

SAT-092 Positive Effect of an Early Start of Growth Hormone Therapy on Auxology and Metabolic Parameters in Children with Prader Willi Syndrome
por: Gohlke, Bettina, et al.
Publicado: (2020)

The Impact of Growth Hormone Therapy on Sleep-Related Health Outcomes in Children with Prader–Willi Syndrome: A Review and Clinical Analysis
por: Zaffanello, Marco, et al.
Publicado: (2023)

Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020)

Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial
por: Yang, Aram, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r4lccjounu3s2nvoc42m2u99ru